Safety Data From the Phase II JULIET Trial in DLBCL

Peter Borchmann, MD, discusses the safety signals seen so far in the phase II JULIET trial investigating tisagenlecleucel, a chimeric antigen receptor T-cell therapy, as a treatment option for patients with diffuse large B-cell lymphoma.

Peter Borchmann, MD, a professor in the department of internal medicine at the University Hospital of Cologne, discusses the safety signals seen so far in the phase II JULIET trial investigating tisagenlecleucel (Kymriah), a chimeric antigen receptor (CAR) T-cell therapy, as a treatment option for patients with diffuse large B-cell lymphoma (DLBCL).

With CAR T-cell therapies, cytokine relapse syndrome (CRS) and neurological events are of special interest in regard to safety. In this study, 58% of patients experienced CRS of some grade, but only 22% of patients experienced grade 3 or greater CRS.